Maryland State Retirement & Pension System Boosts Stock Holdings in Insulet Corporation $PODD

Maryland State Retirement & Pension System raised its holdings in Insulet Corporation (NASDAQ:PODD) by 4.4% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 3,408 shares of the medical instruments supplier’s stock after purchasing an additional 144 shares during the period. Maryland State Retirement & Pension System’s holdings in Insulet were worth $1,071,000 at the end of the most recent reporting period.

Several other large investors have also recently modified their holdings of the business. Sax Wealth Advisors LLC boosted its position in shares of Insulet by 11.1% in the second quarter. Sax Wealth Advisors LLC now owns 3,574 shares of the medical instruments supplier’s stock valued at $1,123,000 after acquiring an additional 357 shares during the period. Knights of Columbus Asset Advisors LLC boosted its position in shares of Insulet by 0.5% in the second quarter. Knights of Columbus Asset Advisors LLC now owns 17,237 shares of the medical instruments supplier’s stock valued at $5,416,000 after acquiring an additional 78 shares during the period. Highland Capital Management LLC bought a new position in shares of Insulet in the second quarter valued at approximately $1,479,000. QRG Capital Management Inc. boosted its position in shares of Insulet by 16.2% in the second quarter. QRG Capital Management Inc. now owns 2,358 shares of the medical instruments supplier’s stock valued at $741,000 after acquiring an additional 328 shares during the period. Finally, Franklin Street Advisors Inc. NC bought a new position in shares of Insulet in the second quarter valued at approximately $346,000.

Analyst Ratings Changes

A number of equities analysts have recently commented on PODD shares. Citigroup restated a “buy” rating on shares of Insulet in a research report on Tuesday, July 8th. The Goldman Sachs Group cut their price objective on shares of Insulet from $399.00 to $375.00 and set a “buy” rating for the company in a research report on Wednesday, October 1st. Jefferies Financial Group restated a “buy” rating on shares of Insulet in a research report on Thursday, August 7th. Piper Sandler lifted their target price on shares of Insulet from $320.00 to $360.00 and gave the company an “overweight” rating in a research report on Tuesday, September 16th. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of Insulet in a research report on Wednesday, October 8th. Seventeen research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, Insulet currently has a consensus rating of “Moderate Buy” and an average target price of $347.67.

Insider Activity at Insulet

In other Insulet news, SVP Laetitia Cousin sold 797 shares of Insulet stock in a transaction that occurred on Monday, September 8th. The shares were sold at an average price of $348.81, for a total transaction of $278,001.57. Following the transaction, the senior vice president directly owned 3,890 shares of the company’s stock, valued at approximately $1,356,870.90. This trade represents a 17.00% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, SVP Prem Singh sold 687 shares of Insulet stock in a transaction that occurred on Monday, September 8th. The stock was sold at an average price of $347.49, for a total transaction of $238,725.63. Following the transaction, the senior vice president directly owned 3,456 shares in the company, valued at $1,200,925.44. This trade represents a 16.58% decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 0.39% of the company’s stock.

Insulet Trading Down 1.8%

Shares of Insulet stock opened at $314.52 on Monday. Insulet Corporation has a 1 year low of $226.50 and a 1 year high of $353.50. The firm has a market cap of $22.14 billion, a PE ratio of 95.60, a PEG ratio of 2.61 and a beta of 1.40. The company has a debt-to-equity ratio of 0.64, a current ratio of 2.26 and a quick ratio of 1.81. The company has a 50 day simple moving average of $323.75 and a two-hundred day simple moving average of $300.64.

Insulet (NASDAQ:PODD) last posted its quarterly earnings results on Thursday, August 7th. The medical instruments supplier reported $1.17 EPS for the quarter, topping the consensus estimate of $0.92 by $0.25. The firm had revenue of $649.10 million for the quarter, compared to the consensus estimate of $612.31 million. Insulet had a net margin of 10.01% and a return on equity of 23.78%. The business’s revenue was up 32.9% compared to the same quarter last year. During the same period last year, the firm posted $0.55 earnings per share. Insulet has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. Analysts expect that Insulet Corporation will post 3.92 earnings per share for the current fiscal year.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.